GH
$22.17
-0.77
(-3.36%)
As of Oct 5, 2026, 5:14 PM EDT · cached
Price history
GH Research (GHRS) is trading down at $22.17 (-3.36%), as of the latest quote. It operates in the Health Care sector.
IPO: June 25, 2021 · $16.00 offering · NASDAQ · View IPO details →
GH Research net income history (FY2019–FY2025)
Net income
| FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Operating income | −$310.0K | −$446.0K | −$15.1M | −$30.6M | −$41.2M | −$50.3M | −$60.7M |
| Net income | −$310.0K | −$446.0K | −$9.20M | −$22.5M | −$35.6M | −$39.0M | −$48.3M |
| EPS (diluted) | −$0.01 | −$0.02 | −$0.21 | −$0.43 | −$0.68 | −$0.75 | −$0.79 |
| Balance sheet | |||||||
| Cash and equivalents | $498.0K | $5.89M | $276.8M | $166.0M | $78.4M | $100.8M | $246.3M |
| Total assets | — | $5.91M | $279.9M | $254.4M | $226.3M | $188.3M | $288.2M |
| Total liabilities | — | $246.0K | $2.75M | $4.55M | $7.33M | $9.32M | $8.53M |
| Shareholders' equity | $400.0K | $5.67M | $277.2M | $249.8M | $219.0M | $179.0M | $279.7M |
| Cash flow | |||||||
| Operating cash flow | −$289.0K | −$330.0K | −$15.3M | −$26.2M | −$33.3M | −$42.3M | −$43.6M |
| Capital expenditure | $0 | $0 | $104.0K | $67.0K | $100.0K | $49.0K | $121.0K |
| Free cash flow | −$289.0K | −$330.0K | −$15.4M | −$26.3M | −$33.4M | −$42.3M | −$43.7M |
Net income
| Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$11.5M | −$13.2M | −$12.6M | −$12.9M | −$12.7M | −$14.7M | −$16.6M | −$16.7M |
| Net income | −$7.67M | −$10.4M | −$12.1M | −$8.80M | −$10.8M | −$9.29M | −$14.0M | −$14.1M |
| EPS (diluted) | −$0.15 | −$0.20 | −$0.23 | −$0.17 | −$0.19 | −$0.15 | −$0.23 | −$0.22 |
| Balance sheet | ||||||||
| Cash and equivalents | $77.5M | $87.1M | $90.1M | $100.8M | $245.0M | $253.9M | $249.7M | $246.3M |
| Total assets | $217.6M | $207.0M | $199.6M | $188.3M | $320.5M | $313.4M | $302.0M | $288.2M |
| Total liabilities | $7.84M | $8.30M | $10.2M | $9.32M | $10.2M | $10.2M | $10.6M | $8.53M |
| Shareholders' equity | $209.7M | $198.7M | $189.4M | $179.0M | $310.2M | $303.2M | $291.4M | $279.7M |
| Cash flow | ||||||||
| Operating cash flow | −$9.60M | −$9.94M | −$12.3M | −$10.4M | −$8.57M | −$8.97M | −$13.7M | −$12.3M |
| Capital expenditure | $12.0K | $8.00K | $4.00K | $25.0K | $4.00K | $59.0K | $39.0K | $19.0K |
| Free cash flow | −$9.61M | −$9.94M | −$12.3M | −$10.5M | −$8.58M | −$9.03M | −$13.7M | −$12.3M |
From GH Research's 20-F and 6-K filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Per-share figures are per ordinary share, which is not always the share traded in the US: an ADS can stand for several, or for part of one. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About GH Research
- Headquarters
- Dublin, Ireland From SEC filings, Oct 2026
Recent News (1)
Other Health Care companies to compare with GHRS
- GDTC CytoMed Therapeutics
- GENB Generate Biomedicines
- GERN Geron Corp
- GH Guardant Health Inc
- GKOS Glaukos Corp
- GLSI Greenwich Lifesciences Inc
- GLUE Monte Rosa Therapeutics Inc
- GMAB Genmab A/s